Revenue Performance - Revenues for the three months ended September 30, 2025, were $303,284, an increase from $200,720 in the same period of 2024, driven by sales of PrecisePRP™ products[146] - Sales of Spryng® products accounted for $186,902, while PrecisePRP™ products contributed $116,382 to total revenues for the three months ended September 30, 2025[146] - Total revenues for the six months ended September 30, 2025, were $600,784, up from $324,470 in the same period of 2024, driven by sales of PrecisePRP™ products[155] Cost and Expenses - Cost of sales increased to $83,226 for the three months ended September 30, 2025, compared to $21,162 in the same period of 2024, primarily due to the introduction of PrecisePRP™ products[147] - Operating expenses decreased to $2,285,425 for the three months ended September 30, 2025, from $2,352,598 in the same period of 2024, attributed to lower general and administrative and research and development expenses[148] - General and administrative ("G&A") expenses decreased to $1,236,730 for Q3 2025 from $1,267,117 in Q3 2024, reflecting cost-cutting initiatives[149] - Sales and marketing expenses increased to $787,262 in Q3 2025 from $620,307 in Q3 2024, driven by support for the launch of Spryng® and PrecisePRP™ products[150] - Research and development ("R&D") expenses decreased to $261,433 in Q3 2025 from $465,174 in Q3 2024, primarily due to reduced clinical studies[151] - Operating expenses decreased to $4,316,468 for the six months ended September 30, 2025, from $4,507,787 in 2024, mainly due to lower G&A and sales and marketing expenses[157] Net Loss - The net loss for the three months ended September 30, 2025, was $3,007,809, compared to a net loss of $2,175,493 for the same period in 2024[145] - Net loss for Q3 2025 was $3,007,809 or ($0.11) per share, compared to a net loss of $2,175,493 or ($0.11) per share in Q3 2024[154] Cash Flow and Assets - The company reported a net cash used in operating activities of $3,828,209 for the six months ended September 30, 2025, primarily due to the net loss and a decrease in accounts payable[166] - As of September 30, 2025, current assets were $2,109,723, with cash and cash equivalents at $767,914, while current liabilities were $1,052,694[164] Product Development and Market Presence - The company has a pipeline of therapeutic devices for both veterinary and human clinical applications, with plans to expand through acquisitions or in-licensing of proprietary products[142] - The company has entered into an Exclusive License and Supply Agreement with VetStem, allowing it to sell PrecisePRP™ products, enhancing its product offerings in the veterinary market[133] - Spryng® has been administered to over 2,000 horses and dogs since its introduction, demonstrating its market acceptance and effectiveness[140] - The company operates from an ISO 7 certified clean room manufacturing facility and plans to open a second facility to minimize supply risks and expand production capacity[141]

Core Insights - PetVivo Holdings, Inc. will hold a conference call on November 14, 2025, to discuss its fiscal second quarter results for the period ending September 30, 2025 [1][2] - The company focuses on innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [4] - PetVivo has a strong product pipeline, including SPRYNG with OsteoCushion technology and PrecisePRP, both currently available for commercial sale [5] Company Overview - PetVivo Holdings, Inc. operates through its subsidiary PetVivo Animal Health, Inc., specializing in biomedical devices for companion animals [4] - The company aims to bring veterinary medical devices to market faster than more regulated pharmaceuticals, enhancing revenue timelines [4] - PetVivo holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and products [5] Upcoming Events - The conference call will include a presentation by management followed by a Q&A session [2] - Dial-in information for the conference call includes a toll-free number and a specific conference ID and passcode [2] - A replay of the conference call will be available on the company's website [3]

Core Insights - PetVivo Holdings, Inc. has appointed Josh Ruben to its Board of Directors, enhancing its leadership team with expertise in healthcare finance and corporate strategy [1][2][4] - Ruben's background includes significant experience in executing multi-billion-dollar mergers and acquisitions, which will support PetVivo's growth and market expansion efforts [2][4] - The company focuses on innovative medical therapeutics for companion animals, particularly in treating osteoarthritis and joint conditions [2][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, specifically targeting the commercialization of medical devices and therapeutics for companion animals [6] - The company aims to leverage human therapies for animal treatment, allowing for a quicker market entry compared to traditional pharmaceuticals [6] - PetVivo has a diverse product pipeline, including its lead product SPRYNG, which utilizes OsteoCushion technology for joint-related afflictions in animals [7] Leadership and Strategy - Josh Ruben, as the Managing Director of Life Sciences at Trinity Capital, brings a wealth of experience in venture lending and investment banking, particularly in life sciences [4][5] - His expertise will be instrumental in guiding PetVivo's capital strategy and maximizing value creation across veterinary and emerging human applications [5] - The company holds a portfolio of twelve patents and six trade secrets, protecting its innovative biomaterials and production processes [7]

Core Insights - PetVivo Holdings, Inc. has entered into a 10-year exclusive white-label licensing agreement with Digital Landia Holding Corp for the Agentic Pet AI technology, aimed at addressing high client acquisition costs and engaging the growing Gen Z pet parent demographic [1][13]. Industry Overview - The veterinary industry is experiencing a demographic shift, with Gen Z pet parenthood increasing by 43.5% in 2024, making Gen Z and Millennials account for 57% of all pet parents in the U.S. [3][5]. - Traditional marketing strategies in veterinary practices are failing to connect with the tech-savvy Gen Z demographic, which presents a significant opportunity for innovative solutions [5]. Technology and Solutions - The Agentic Pet AI technology can reduce client acquisition costs by 90% to 98%, lowering costs from $50-$150+ per client to just $1.50-$5.00 per targeted outreach [2][9]. - The technology includes a freemium app with nine specialized AI diagnostic agents that track pet health, allowing pet parents to share health data seamlessly with veterinary practices [7][8]. Economic Impact - The partnership is expected to transform client acquisition for veterinary practices, with a case study showing a reduction in acquisition costs from $80-$120 to $3.50 per client, alongside significant time savings in patient history gathering [11][12]. - The overall efficiency of consultations is projected to improve by 20%, with a 30% increase in preventive care visits due to early issue identification through AI [12]. Market Opportunity - PetVivo is entering a $4.9 billion U.S. veterinary AI market with over 30,000 addressable clinics, leveraging existing relationships with more than 1,000 veterinary clinics for immediate distribution [14]. - The company reported a 141% year-over-year growth in Q1 FY2026, with fiscal 2025 revenue reaching $1.13 million, indicating strong market momentum [14]. Strategic Positioning - The exclusive agreement provides PetVivo with a competitive advantage for 10 years, creating multiple revenue streams through B2B subscriptions and lead generation fees [15]. - The dual-platform launch in Q1 2026 is expected to create immediate network effects, enhancing the value proposition for both pet parents and veterinary practices [13].

Core Insights - PetVivo Animal Health, Inc. has entered into a Vendor Partner Agreement with Veterinary Growth Partners to promote its innovative veterinary products [1][5] - The agreement aims to enhance the accessibility and adoption of PetVivo's flagship products, Spryng with OsteoCushion Technology and PrecisePRP, among veterinary practices [2][5] Company Overview - PetVivo Holdings, Inc. is focused on the commercialization of biomedical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment solutions [6][7] - The company has a robust pipeline of products protected by twelve patents and six trade secrets, including Spryng and PrecisePRP [7] Product Details - Spryng with OsteoCushion Technology is an intra-articular injectable device designed to manage joint pain and improve joint mechanics in animals [3] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product that provides a consistent dose of 4 billion platelets per vial, designed for easy use by veterinarians [4] Partnership Impact - The collaboration with Veterinary Growth Partners is expected to expand national availability and enhance purchasing efficiency for veterinary practices seeking non-pharmaceutical solutions [5][8] - Veterinary Growth Partners supports over 7,300 veterinary members across the U.S., providing a significant network for PetVivo's products [1][2]

Core Insights - PetVivo Holdings, Inc. has entered into note conversion agreements with four existing shareholders to convert $2,018,155 of outstanding promissory notes into 3,669,806 shares of common stock, effectively eliminating over $2 million of debt from its balance sheet [1][4] Group 1: Financial Developments - The total outstanding debt consisted of a principal amount of $1,850,000 and accrued interest of $168,155 [1] - The conversion prices of the notes ranged from $0.50 to $0.75 per share [1] - The successful completion of the note conversion strengthens the company's financial position and allows for more resources to be directed towards product commercialization [4] Group 2: Product Information - PetVivo's signature products include SPRYNG with OsteoCushion Technology, an injectable veterinary medical device that aids in managing joint pain and restoring joint mechanics [2][7] - PrecisePRP is a first-in-class, off-the-shelf platelet-rich plasma product designed for intra-articular administration in dogs and horses, providing a consistent dose of 4 billion platelets per vial [3][7] Group 3: Company Overview - PetVivo Holdings, Inc. focuses on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals [6] - The company has a robust pipeline of products protected by twelve patents and six trade secrets [7]

Core Insights - PetVivo Animal Health has launched three new continuing education courses aimed at veterinary professionals, focusing on osteoarthritis, joint injection techniques, and regenerative modalities for small animals and equines [1][4]. Course Offerings - The courses are RACE-approved and provide 1.0 credit hour each, developed by practicing veterinarians with expertise in surgery and rehabilitation [2][3]. - Course topics include: - An introductory overview of osteoarthritis pathophysiology and multimodal management strategies [7]. - Advanced exploration of joint injections, including biomechanics and treatment modalities [7]. - Examination of equine osteoarthritis and the scientific rationale for regenerative therapies [7]. Company Commitment - PetVivo Animal Health emphasizes a commitment to advancing regenerative medicine in veterinary practice, focusing on disease-modifying potential and clinical applications [4]. - The courses are offered at no cost to veterinarians, veterinary technicians, and allied professionals, reflecting the company's dedication to education and professional development [5]. Company Overview - PetVivo Animal Health is a subsidiary of PetVivo Holdings, Inc., specializing in veterinary medical devices and regenerative therapies for managing osteoarthritis and joint-related conditions [6]. - The company's product portfolio includes Spryng with OsteoCushion Technology and PrecisePRP, aimed at providing long-term joint support and improving animal mobility and quality of life [6].

Summary of PetVivo Holdings Conference Call Company Overview - **Company Name**: PetVivo Holdings - **Ticker Symbol**: PETV - **Market Focus**: Companion animal veterinary care market, valued at approximately $11 billion [2][19] Core Products - **Spryng with OsteoCushion Technology**: A veterinary medical device designed to restore joint mechanics and address osteoarthritis in animals. It is classified as a human medical device, allowing it to bypass FDA review for veterinary use [2][8]. - **PrecisePRP**: An allogenic freeze-dried platelet-rich plasma product, the only FDA-reviewed product for safety that does not require blood drawing from the animal [2][17]. Market Dynamics - **Osteoarthritis Prevalence**: Approximately 80% of dogs will develop osteoarthritis by age eight, with symptoms often starting as early as three to four years old [4]. - **Current Treatment Limitations**: Existing treatments primarily mask symptoms rather than address the root cause, leading to potential long-term damage [5][12]. Competitive Advantages - **Unique Mechanism of Action**: Spryng addresses the underlying issues of joint degradation rather than just alleviating pain, providing a longer-lasting solution (up to 12 months) compared to other treatments [6][8]. - **Cost-Effectiveness**: Spryng's pricing ranges from $600 to $1,200 per injection, which is competitive compared to monthly treatments like Librela costing around $150 [31][32]. - **Strong Intellectual Property Portfolio**: PetVivo holds 12 U.S. patents and 9 foreign patents, with ongoing efforts to expand this portfolio [3][9]. Distribution and Expansion - **Distribution Agreements**: Established partnerships with major distributors in the U.S. and recent expansions into Mexico and the UK [3][27]. - **Market Growth**: The pet care market is considered recession-proof, with increasing spending on veterinary care as pets are viewed as family members [19]. Clinical Evidence and Studies - **Successful Clinical Trials**: Over 12,000 injections have been administered with positive outcomes, including a study showing a 77% improvement in dogs with late-stage hip issues [10][15][16]. - **Ongoing Research**: Multiple clinical trials are underway, including studies at Colorado State University, aimed at further validating the efficacy of Spryng [16][24]. Future Outlook - **Product Pipeline**: Plans to expand into human markets and develop additional veterinary applications [22][29]. - **Regulatory Support**: The product has received endorsements from regulatory bodies, enhancing its credibility in the market [28]. Management and Team - **Experienced Leadership**: The management team includes individuals with extensive backgrounds in both veterinary and human healthcare sectors, contributing to the company's strategic direction [26][27]. Conclusion PetVivo Holdings is positioned to capitalize on the growing demand for effective veterinary treatments, particularly for osteoarthritis, through its innovative products and strong market presence. The company aims to leverage its unique technology and distribution partnerships to drive future growth and expand into new markets.

Core Viewpoint - PetVivo Holdings, Inc. is set to present at the Life Sciences Virtual Investor Forum on September 18, 2025, highlighting its innovative medical devices and therapeutics for animals [1][4]. Company Overview - PetVivo Holdings, Inc. is an emerging biomedical device company focused on the commercialization of medical devices and therapeutics for horses and companion animals [5]. - The company aims to leverage human therapies for animal treatment in a capital and time-efficient manner, with a strategy that allows for accelerated revenue timelines compared to pharmaceuticals [5]. Product Information - PetVivo has a robust pipeline of products, including SPRYNG™ with OsteoCushion™ technology for managing joint-related afflictions in animals and PrecisePRP, a first-in-class platelet-rich plasma product [6]. - The company holds a portfolio of twelve patents and six trade secrets that protect its biomaterials and production processes [6]. Event Details - The Life Sciences Virtual Investor Forum will take place on September 18, 2025, from 11:00 to 11:30 am ET, allowing real-time interaction between investors and the company [2]. - Archived webcasts will be available for those unable to attend the live event [2].

Core Points - PetVivo Animal Health, Inc. has entered into a distribution agreement with Nupsala Limited to market its veterinary medical device, Spryng with OsteoCushion technology, in the United Kingdom [1][2] - The distribution activities by Nupsala commenced on September 1, 2025, aiming to enhance the accessibility of Spryng to veterinarians and animal owners [1][2] - Spryng with OsteoCushion technology is designed to manage joint pain in animals by promoting proper joint mechanics and integrating with subsynovial tissue [3][4] Company Overview - PetVivo Holdings, Inc. focuses on the commercialization of innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [5] - The company has a robust pipeline of products, including Spryng and PrecisePRP, and holds a portfolio of twenty-one patents protecting its biomaterials and methods [6] Partner Overview - Nupsala Limited specializes in musculoskeletal health and regenerative medicine for companion animals and horses, operating as both a veterinary wholesaler and referral provider [8][9] - Nupsala aims to improve animal mobility and deliver innovative solutions through clinical trials, diagnostics, and educational initiatives [9]